João Alessi, MD
@alessi_joao
Followers
799
Following
6K
Statuses
429
Medical Oncology Hospital Sírio-Libanês. Clinical research fellow at Dana-Farber Cancer Institute.
São Paulo, Brasil
Joined June 2017
RT @jitcancer: New #JITC article: Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pe…
0
11
0
RT @DrJNaidoo: How do copy no. deletions in STK11, KEAP1 &SMARCA4 impact outcomes in NSCLC? -3194 nonsqNSCLCs: 14.7% STK11del 13.5% KEAP1d…
0
34
0
RT @StephenVLiu: Will the future of lung cancer biomarkers be based on deep learning and #AI? Deep learning model predicts response to immu…
0
18
0
RT @BiagioRicciutMD: Datopotamab Deruxtecan in Advanced or Metastatic #NCLC With Actionable Genomic Alterations: Phase II TROPION-Lung05 St…
0
11
0
RT @BiagioRicciutMD: 🚨Glad to see this collaborative effort finally out in @JAMAOnc! We developed a deep learning model (#DeepIO) to predi…
0
19
0
RT @adib_elio: ⚠️Great to keep contributing to this ongoing effort by #MehrdadRakaee and collaborators! @DanaFarber Histology slides are w…
0
5
0
RT @OncoAlert: Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer Out on @JAMAOnc This stu…
0
23
0
RT @JCOPO_ASCO: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in #NSCLC Harboring BRAF Class 3 Mutations: https://t.…
0
3
0
RT @DiFedericoMD: Mucinous lung adenocarcinoma (LUAD-Muc) is a WHO-recognized rare subtype of LUAD. Our study in @Annals_Oncology aimed to…
0
22
0
RT @BiagioRicciutMD: Great talk by @lmsholl at #MaTOS 24 on how to best assess response to neoadjuvant/perioperative chemo-immunotherapy in…
0
7
0
RT @StephenVLiu: First report of response to tarlatamab in a patient with atypical carcinoid @JTOonline. Multiple prior lines of therapy -…
0
25
0
RT @Annals_Oncology: 📢Article of the Month: Dr Alessandro Di Federico introduces: Intrapatient variation in PD-L1 expression and tumor mut…
0
11
0
RT @DiFedericoMD: Honored to have our work highlighted in this month’s issue of @Annals_Oncology. Many thanks to my mentor @DrMarkAwad, to…
0
6
0
RT @StephenVLiu: Case report of #MET mediating resistance to entrectinib in #ROS1 NSCLC with subsequent (transient) response to crizotinib.…
0
12
0
RT @RobertoFerrara_: Perioperative not better than neoadjuvant ICI in both pCR and non-pCR NSCLC. Postoperative ICI must be tailored in a…
0
28
0
RT @carisls: What treatment strategy is most effective in advanced large cell neuroendocrine tumors (LCNEC)? @AminNassarMD from @YaleIBIO s…
0
4
0
RT @MSKCancerCenter: We'd like to welcome @DrMarkAwad, MSK's new Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Div…
0
5
0
RT @IASLC: In this #LungCancerConsidered episode, @NarjustFlorezMD & 2 esteemed oncology colleagues discuss an evolving hot topic: the use…
0
4
0
RT @GBOT_Alerta: 🚨Escherichia intratumoral e eficácia ICI em CPCNPm: - Mapeamento de microbioma intracelular em coorte de 958 pcts com val…
0
3
0